{"id":1318,"date":"2021-12-04T10:47:18","date_gmt":"2021-12-04T02:47:18","guid":{"rendered":"https:\/\/www.bebi.ntu.edu.tw\/?p=1318"},"modified":"2022-02-14T10:55:41","modified_gmt":"2022-02-14T02:55:41","slug":"%e7%94%9f%e9%86%ab%e9%9b%bb%e8%b3%87%e6%89%80%e6%95%99%e5%b8%ab%e7%a0%94%e7%a9%b6%e4%ba%ae%e9%bb%9e-12%e6%9c%88%e4%bb%bd%e3%80%8c%e9%98%ae%e9%9b%aa%e8%8a%ac%e6%95%99%e6%8e%88%e3%80%8d","status":"publish","type":"post","link":"https:\/\/www.bebi.ntu.edu.tw\/?p=1318","title":{"rendered":"\u751f\u91ab\u96fb\u8cc7\u6240\u6559\u5e2b\u7814\u7a76\u4eae\u9ede-110\u5e7412\u6708\u4efd\u300c\u962e\u96ea\u82ac\u6559\u6388\u300d"},"content":{"rendered":"<p>\u7814\u7a76\u4e3b\u984c\uff1aTherapeutic Targeting of Non-oncogene Dependencies in High-risk Neuroblastoma\u795e\u7d93\u6bcd\u7d30\u80de\u7624\u662f\u4e00\u7a2e\u6e90\u65bc\u5468\u570d\u4ea4\u611f\u795e\u7d93\u7cfb\u7d71\u7684\u60e1\u6027\u816b\u7624\uff0c\u767c\u751f\u65bc\u5152\u7ae5\u65e9\u671f\u3002\u800cMYCN\u81f4\u764c\u57fa\u56e0\u7684\u64f4\u589e\u5df2\u88ab\u8b49\u660e\u662f\u9a45\u52d5\u795e\u7d93\u6bcd\u7d30\u80de\u7624\u7684\u767c\u75c5\u6a5f\u5236\u4e4b\u4e00\uff0c\u4e26\u8207\u9ad8\u5371\u96aa\u7fa4\u7684\u60a3\u8005\u76f8\u95dc\u3002\u7136\u800c\uff0c\u7531\u65bc\u7f3a\u4e4f\u7a81\u8b8a\u548c\u5206\u5b50\u7570\u8cea\u6027\uff0c\u4f7f\u5f97\u6a19\u9776\u6cbb\u7642\u7684\u767c\u5c55\u53d7\u5230\u9650\u5236\u3002\u70ba\u4e86\u627e\u5230\u65b0\u7a4e\u4e14\u6709\u6548\u7684\u6cbb\u7642\u65b9\u6cd5\uff0c\u672c\u7814\u7a76\u5f9eGEO\u8cc7\u6599\u96c6\u4e2d\u5c0d\u8fd1\u5343\u540d\u539f\u767c\u6027\u795e\u7d93\u6bcd\u7d30\u80de\u7624\u60a3\u8005\u9032\u884c\u7d9c\u5408\u5206\u6790\uff0c\u4e26\u9810\u6e2c\u91dd\u5c0d\u9ad8\u98a8\u96aa\u795e\u7d93\u6bcd\u7d30\u80de\u7624\u975e\u764c\u57fa\u56e0\u4f9d\u8cf4\u6027\u7684\u6f5b\u5728\u85e5\u7269\u3002\u6b64\u5916\uff0c\u5728\u8001\u9f20\u9ad4\u5167\u9a57\u8b49\u4e86\u8010\u514b\u87ba(\u4e00\u7a2eFDA\u6279\u51c6\u6cbb\u7642\u7d5b\u87f2\u611f\u67d3\u7684\u9a45\u87f2\u85e5\u7269)\u7684\u6297\u795e\u7d93\u6bcd\u7d30\u80de\u7624\u6d3b\u6027\uff0c\u4e26\u900f\u904e\u86cb\u767d\u8cea\u9ad4\u5b78\u7814\u7a76\u5176\u6a5f\u5236\u3002\u8a72\u7814\u7a76\u8b49\u660e\u5229\u7528\u539f\u767c\u795e\u7d93\u6bcd\u7d30\u80de\u7624\u7684\u8f49\u9304\u5716\u8b5c\u548c\u5c0f\u5206\u5b50\u9032\u884c\u85e5\u7269\u958b\u767c\u7684\u53ef\u80fd\u6027\uff0c\u4e26\u70ba\u8010\u514b\u87ba\u6cbb\u7642\u795e\u7d93\u6bcd\u7d30\u80de\u7624\u7684\u81e8\u5e8a\u7642\u6548\u63d0\u4f9b\u4e86\u6a5f\u6703\u3002Neuroblastoma is a malignant tumor arising in the peripheral sympathetic nervous system. It typically occurs in early childhood. It has been shown that genomic amplification of MYCN oncogene driving neuroblastoma pathogenesis. And it is related to stratify patients into neuroblastoma risk groups. However, the development of targeted therapies is limited due to the paucity of mutations and molecular heterogeneity. To find new therapeutic approaches and effective treatments, this research performs integrative analysis of nearly a thousand patients with primary neuroblastoma tumors obtained from multiple Gene Expression Omnibus (GEO) datasets and identify potential drugs that target non-oncogene dependencies in high-risk neuroblastoma. Furthermore, the therapeutic efficacy of niclosamide, an anthelmintic drug approved by the FDA to treat tapeworm infections, is also demonstrated in vivo and investigated the mechanism through proteomics. The study exhibits the feasibility of using transcriptional profiling of primary neuroblastomas and small-molecule treatments for drug discovery and provides an opportunity for the clinical efficacy of niclosamide in the treatment of high-risk neuroblastoma.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>\u7814\u7a76\u4e3b\u984c\uff1aTherapeutic Targeting of Non-oncogene Dependencies [&#8230;]\n","protected":false},"author":2,"featured_media":1320,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[19],"tags":[],"class_list":["post-1318","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-award"],"jetpack_featured_media_url":"https:\/\/www.bebi.ntu.edu.tw\/wp-content\/uploads\/2022\/02\/Therapeutic-Targeting-of-Non-oncogene-Dependencies-in-High-risk-Neuroblastoma.jpg","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/www.bebi.ntu.edu.tw\/index.php?rest_route=\/wp\/v2\/posts\/1318","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.bebi.ntu.edu.tw\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.bebi.ntu.edu.tw\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.bebi.ntu.edu.tw\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.bebi.ntu.edu.tw\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=1318"}],"version-history":[{"count":3,"href":"https:\/\/www.bebi.ntu.edu.tw\/index.php?rest_route=\/wp\/v2\/posts\/1318\/revisions"}],"predecessor-version":[{"id":1325,"href":"https:\/\/www.bebi.ntu.edu.tw\/index.php?rest_route=\/wp\/v2\/posts\/1318\/revisions\/1325"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.bebi.ntu.edu.tw\/index.php?rest_route=\/wp\/v2\/media\/1320"}],"wp:attachment":[{"href":"https:\/\/www.bebi.ntu.edu.tw\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=1318"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.bebi.ntu.edu.tw\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=1318"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.bebi.ntu.edu.tw\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=1318"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}